Breaking News

Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Orpharm LLC for its Lead Asset, QRX003, for Netherton Syndrome

Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Orpharm LLC for its Lead Asset, QRX003, for Netherton Syndrome


Orpharm Gains Unique Rights to Commercialize QRX003 in Russia and CIS

ASHBURN, Va., Dec. 15, 2021 (Globe NEWSWIRE) — Quoin Prescribed drugs Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical enterprise targeted on uncommon and orphan conditions, nowadays introduced that its wholly-owned subsidiary, Quoin Prescribed drugs, Inc., has entered into an exceptional Distribution Agreement with Orpharm LLC (“Orpharm”) for QRX003, the Company’s investigational cure for Netherton Syndrome, a uncommon and devastating genetic sickness, for which there is at this time no obtainable remedy or treatment.

Less than the phrases of the agreement, Orpharm gains unique rights to commercialize QRX003 in Russia and CIS, and Quoin is obligated to supply the product or service to Orpharm, upon the receipt of regulatory approval.

Dr. Michael Myers, Chief Govt Officer of Quoin, commented, “This distribution arrangement with Orpharm is our third partnership settlement for QRX003 in less than two months and underscores Quoin’s determination to make our merchandise obtainable to as numerous sufferers as possible upon the receipt of regulatory acceptance. We are very delighted that Orpharm has turn into our husband or wife for Russia and CIS and we glance ahead to doing the job with them to provide this possible treatment method to a really underserved individual populace.”

“We are psyched to lover with Quoin. QRX003 will be a a great deal required remedy to patients suffering from Netherton syndrome in our area. We are committed to supporting Quoin and leveraging our associations with dermatologists and the broader unusual sickness local community,” states Pavel Shestiperov, M.D., CEO of Orpharm.

About Netherton Syndrome

Netherton Syndrome, a form of Ichthyosis, is a uncommon, hereditary pores and skin ailment brought about by a mutation in the SPINK5 gene (serine protease inhibitor, Kazal Kind 5) that potential customers to severe skin barrier problems and recurring infections, as perfectly as a pronounced predisposition to allergies, bronchial asthma, and eczema. Sufferers also usually endure from critical dehydration, long-term pores and skin swelling and stunted advancement.

Currently, there is no overcome for Netherton Syndrome, nor are there any accepted therapeutic treatment plans.

About Orpharm LLC

Orpharm LLC was founded in 2019 with the aim to be the major complete support distributor for exceptional illnesses, oncology and highly specialized therapeutics in Russia & CIS. Orpharm has an equivalent emphasis on client demand generation as a result of proof-primarily based medicine, quick observe market place access options, and the greatest compliance & moral expectations, all while striving for the best results for clients, prescribers, and associates.

Orpharm is also a very pleased founding member of the Environment Orphan Drug Alliance (WODA) supplying its solutions together with like-minded sister businesses in Switzerland, CEE, Middle East & Turkey, and Latin The us.

About Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd. is an emerging specialty pharmaceutical corporation concentrated on creating and commercializing therapeutic solutions that treat rare and orphan illnesses. We are dedicated to addressing unmet clinical requirements for sufferers, their households, communities and care groups. Quoin’s ground breaking pipeline includes a few products in improvement that collectively have the prospective to focus on a broad range of scarce and orphan indications, together with Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa and some others. For extra facts, go to: www.quoinpharma.com.

Cautionary Be aware Regarding Ahead Seeking Statements

The Company cautions that statements in this push release that are not a description of historic details are ahead-hunting statements in just the which means of the Private Securities Litigation Reform Act of 1995. Ahead-seeking statements might be discovered by the use of text referencing long run functions or conditions these types of as “anticipate,” “intend,” “program,” “foresee,” “think,” and “will,” amid other people. Mainly because these kinds of statements are subject matter to threats and uncertainties, precise success might differ materially from those expressed or implied by these types of forward-hunting statements. These ahead-searching statements are dependent on the Company’s current anticipations and require assumptions that may perhaps never materialize or may well prove to be incorrect. True benefits and the timing of occasions could vary materially from people expected in this kind of ahead-hunting statements as a consequence of different challenges and uncertainties. A lot more comprehensive data about the challenges and uncertainties impacting the Firm is contained underneath the heading “Threat Factors” integrated in the Company’s Yearly Report on Kind 20-F submitted with the SEC on March 29, 2021 and in other filings the Business has designed and may well make with the SEC in the future. Just one really should not area undue reliance on these ahead-hunting statements, which speak only as of the date on which they had been made. Simply because these kinds of statements are subject matter to pitfalls and uncertainties, precise outcomes may vary materially from those people expressed or implied by these kinds of ahead-on the lookout statements. The Firm undertakes no obligation to update such statements to reflect events that come about or instances that exist after the date on which they were built, except as may well be essential by law.

For additional information and facts, speak to:

Quoin Prescription drugs Ltd.
Michael Myers, Ph.D., CEO
[email protected]

Trader Relations
PCG Advisory
Jeff Ramson
[email protected]
(646) 863-6341



Resource link